LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

Search

Heron Therapeutics Inc

Avatud

SektorTervishoid

1.24

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.23

Max

1.25

Põhinäitajad

By Trading Economics

Sissetulek

-5M

-2.4M

Müük

-1.7M

37M

Kasumimarginaal

-6.401

Töötajad

122

EBITDA

-5.3M

-1.6M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+262.9% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

11. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-68M

199M

Eelmine avamishind

1.24

Eelmine sulgemishind

1.24

Uudiste sentiment

By Acuity

43%

57%

165 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Heron Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. sept 2025, 22:39 UTC

Omandamised, ülevõtmised, äriostud

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15. sept 2025, 16:43 UTC

Suurimad hinnamuutused turgudel

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15. sept 2025, 16:42 UTC

Suurimad hinnamuutused turgudel

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15. sept 2025, 16:35 UTC

Suurimad hinnamuutused turgudel

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15. sept 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. sept 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15. sept 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15. sept 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15. sept 2025, 22:12 UTC

Omandamised, ülevõtmised, äriostud

CSL Expects Commercial Launch in 2029

15. sept 2025, 22:12 UTC

Omandamised, ülevõtmised, äriostud

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15. sept 2025, 22:11 UTC

Omandamised, ülevõtmised, äriostud

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15. sept 2025, 22:11 UTC

Omandamised, ülevõtmised, äriostud

CSL to Have Right to Exercise Option Based on Phase 3 Data

15. sept 2025, 22:10 UTC

Omandamised, ülevõtmised, äriostud

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15. sept 2025, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15. sept 2025, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15. sept 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15. sept 2025, 21:14 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15. sept 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. sept 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. sept 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15. sept 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15. sept 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15. sept 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15. sept 2025, 17:50 UTC

Omandamised, ülevõtmised, äriostud

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15. sept 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. sept 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15. sept 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15. sept 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15. sept 2025, 16:20 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

262.9% tõus

12 kuu keskmine prognoos

Keskmine 4.5 USD  262.9%

Kõrge 6 USD

Madal 3 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Heron Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

2.0001 / 2.42Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

165 / 371 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat